Abstract
In the early 1980s, an atypical beta-adrenergic receptor was discovered and subsequently called the beta3 -adrenoceptor (beta3 -AR). Agonists of the beta3 -AR were observed to simultaneously increase lipolysis, fat oxidation, energy expenditure and insulin action leading to the belief that this receptor might serve as an attractive target for the treatment of diabetes and obesity. In vivo studies lent credence to this postulate with the finding that stimulation of this receptor by selective agonists lead to glycemic improvements and weight loss in rodent models of diabetes and obesity. This lead to intensive research efforts directed at developing beta3 -AR selective agonists for the treatment of type 2 diabetes and obesity in humans. Unfortunately, endeavour been largely unsuccessful to date. Major obstacles have included the pharmacological differences between the rodent and human beta3 -AR, the lack of selectivity of previous compounds for the beta3 -AR over beta1 - / beta2 -ARs, and unsatisfactory oral bioavailability and pharmacokinetic properties. Cloning of the human beta3 -AR has allowed for the development of novel compounds targeted specifically at the human receptor. Encouraging data has emerged from clinical studies wherein CL-316,243, a highly selective, albeit rodent specific beta3 -AR agonist was observed to increase lipolysis, fat oxidation and insulin action in humans. More recently, beta3 -AR agonists directed at the human receptor are showing promising results in their ability to increase energy expenditure in humans following a single dose. However, they do not appear to be able to sustain their effects when administered chronically. Further clinical testing will be necessary, using compounds with improved oral bioavailability and potency, to help assess the physiology of the beta3 -AR in humans and its attractiveness as a potential therapeutic for the treatment of type 2 diabetes and obesity.
Keywords: Beta3 -Adrenoceptor Agonists, Anti-diabetic, Anti-obesity Drugs
Current Pharmaceutical Design
Title: Beta3 -Adrenoceptor Agonists as Anti-diabetic and Anti-obesity Drugs in Humans
Volume: 7 Issue: 14
Author(s): Christopher J. de Souza and Bryan F. Burkey
Affiliation:
Keywords: Beta3 -Adrenoceptor Agonists, Anti-diabetic, Anti-obesity Drugs
Abstract: In the early 1980s, an atypical beta-adrenergic receptor was discovered and subsequently called the beta3 -adrenoceptor (beta3 -AR). Agonists of the beta3 -AR were observed to simultaneously increase lipolysis, fat oxidation, energy expenditure and insulin action leading to the belief that this receptor might serve as an attractive target for the treatment of diabetes and obesity. In vivo studies lent credence to this postulate with the finding that stimulation of this receptor by selective agonists lead to glycemic improvements and weight loss in rodent models of diabetes and obesity. This lead to intensive research efforts directed at developing beta3 -AR selective agonists for the treatment of type 2 diabetes and obesity in humans. Unfortunately, endeavour been largely unsuccessful to date. Major obstacles have included the pharmacological differences between the rodent and human beta3 -AR, the lack of selectivity of previous compounds for the beta3 -AR over beta1 - / beta2 -ARs, and unsatisfactory oral bioavailability and pharmacokinetic properties. Cloning of the human beta3 -AR has allowed for the development of novel compounds targeted specifically at the human receptor. Encouraging data has emerged from clinical studies wherein CL-316,243, a highly selective, albeit rodent specific beta3 -AR agonist was observed to increase lipolysis, fat oxidation and insulin action in humans. More recently, beta3 -AR agonists directed at the human receptor are showing promising results in their ability to increase energy expenditure in humans following a single dose. However, they do not appear to be able to sustain their effects when administered chronically. Further clinical testing will be necessary, using compounds with improved oral bioavailability and potency, to help assess the physiology of the beta3 -AR in humans and its attractiveness as a potential therapeutic for the treatment of type 2 diabetes and obesity.
Export Options
About this article
Cite this article as:
de Souza J. Christopher and Burkey F. Bryan, Beta3 -Adrenoceptor Agonists as Anti-diabetic and Anti-obesity Drugs in Humans, Current Pharmaceutical Design 2001; 7 (14) . https://dx.doi.org/10.2174/1381612013397339
DOI https://dx.doi.org/10.2174/1381612013397339 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives
Current Medicinal Chemistry Targeting the AMP-Activated Protein Kinase for the Treatment of Type 2 Diabetes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Pulmonary Complications in Diabetes Mellitus: The Role of Glycemic Control
Current Drug Targets - Inflammation & Allergy Stem Cells Derived from Human Exfoliated Deciduous Teeth (SHED) in Neuronal Disorders: A Review
Current Stem Cell Research & Therapy Biochemical Markers and Risk Factors of Alzheimers Disease
Current Alzheimer Research Editorial [Hot Topic: New Prospects for Treatment of Autoimmune Diseases (Executive Guest Editor: Alessandra Fierabracci)]
Current Pharmaceutical Design Editorial [Hot Topic: Drugs Targeted to Improve Endothelial Function: Clinical Correlates Between Sexual and Internal Medicine (Executive Editor: Antonio Aversa)]
Current Pharmaceutical Design Emerging Trends On Drug Delivery Strategy of Momordica charantia against Diabetes and its Complications
Current Drug Delivery Discovery of Novel Anti-Diabetic Drugs by Targeting Lipid Metabolism
Current Drug Targets Biodegradable Polymer Based Particulate Carrier(s) for the Delivery of Proteins and Peptides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design Branched-Chain Amino Acids and Pigment Epithelium-Derived Factor: Novel Therapeutic Agents for Hepatitis C Virus-Associated Insulin Resistance
Current Medicinal Chemistry How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with the Metabolic Syndrome?
Vascular Disease Prevention (Discontinued) Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Microvascular Alterations in Hypertension and Vascular Aging
Current Hypertension Reviews Chronic Inflammation: Role of Adipose Tissue and Modulation by Weight Loss
Current Diabetes Reviews The Relationship Between Inflammation, Dyslipidemia and Physical Exercise: From the Epidemiological to Molecular Approach
Current Diabetes Reviews Emerging Role of Stromal Fibroblasts in Epithelial Cancer
Current Signal Transduction Therapy Role of Oxidative Stress in the Development of Vascular Injury and its Therapeutic Intervention by Nifedipine
Current Medicinal Chemistry